The FDA has approved a new freeze-dried formulation of Jynneos (smallpox and mpox vaccine, live, non-replicating).

Even though the virus was first discovered in laboratory monkeys in 1958, the original source came from a squirrel.

STAT senior writer for infectious disease Helen Branswell answers the most frequently asked questions about what is happening with mpox now and what can be done to stop this current outbreak. In ...

She is passionate about empowering others to protect life's most important assets. Wh... Michelle is a lead editor at Forbes Advisor. She has been a journalist for over 35 years, writing about ...

Mpox is shifting from an animal-borne virus to one that spreads easily between people, raising global concerns. Mutations may be helping it adapt, making it harder to control. Credit: NIAID/NIH Mpox, ...

The freeze-dried formulation provides flexibility with regard to storage and shelf life. The Food and Drug ... formulation of Jynneos ® (smallpox and mpox vaccine, live, non-replicating).

The MVA-BN vaccine showed an overall effectiveness of 57.8% (95% CI, 11.8-83.0) in reducing mpox cases at 14 days or longer after the first dose; however, the effectiveness was lower in people ...

EQS-News: GeoVax, Inc. / Key word (s): Financial GeoVax Reports 2024 Year-End Financial Results and Provides Business Update 27.03.2025 / 21:06 CET/CEST The issuer is solely responsible for the ...

The need for these measures is critical and urgent, as evidenced by the recent Mpox public health emergency declaration by the World Health Organization. GeoVax remains committed to bolstering ...